PDF herunterladen
CC BY-NC-ND 4.0 · World J Nucl Med 2019; 18(04): 431-433
DOI: 10.4103/wjnm.WJNM_76_18
Case Report

Metastatic large cell neuroendocrine carcinoma of larynx: Individualizing tumor biology by dual tracer positron emission tomography/computed tomography (68Ga-DOTATATE and 18F-fluorodeoxyglucose) molecular imaging and disease stabilization following 177Lu-DOTATATE peptide receptor radionuclide therapy after initial progression on chemoradiotherapy

Sonali Jadhav
1   Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, India
2   Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Sandip Basu
1   Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, India
2   Homi Bhabha National Institute, Mumbai, Maharashtra, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Debate exists on the disease biology and course of primary large cell neuroendocrine carcinoma (LCNEC) of larynx, being classified as a variant of atypical carcinoid by the World Health Organisation-2005 classification, while literature of its aggressive behavior indicating poorly differentiated neuroendocrine carcinoma (akin to pulmonary LCNEC) exists. The utility of dual tracer positron emission tomography/computed tomography (68Ga-DOTATATE and 18F-fluorodeoxyglucose) in deciphering the dynamic tumor biology and feasibility of peptide receptor radionuclide therapy (PRRT) is illustrated in metastatic LCNEC of epiglottis after disease progression following conventional chemoradiotherapy. Relatively, atypical sites of soft-tissue metastases (subcutaneous tissue of arm, scrotal sac, peritoneum, and lamina of thyroid cartilage) and xiphisternum and disease stabilization following 177Lu-DOTATATE PRRT were other noteworthy unique aspects of this report.

Keywords

177Lu-DOTATATE - 18F-fluorodeoxyglucose - 68Ga-DOTATATE - carcinoma larynx - dual tracer positron emission tomography-computed tomography - large cell neuroendocrine carcinoma - peptide receptor radionuclide therapy

Financial support and sponsorship

Nil.




Publikationsverlauf

Eingereicht: 13. September 2018

Angenommen: 02. Dezember 2018

Artikel online veröffentlicht:
22. April 2022

© 2019. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ferlito A, Silver CE, Bradford CR, Rinaldo A. Neuroendocrine neoplasms of the larynx: An overview. Head Neck 2009;31:1634-46.
  • 2 Barnes EL, Eveson JW, Reichart P, Sidransky D, editors. Pathology and Genetics of Head and Neck Tumours. In: Kleihues P, Sobin LH, editors. World Health Organization Classification of Tumours. Lyon: IARC Press; 2005.
  • 3 Lewis JS Jr., Spence DC, Chiosea S, Barnes EL Jr., Brandwein-Gensler M, El-Mofty SK, et al. Large cell neuroendocrine carcinoma of the larynx: Definition of an entity. Head Neck Pathol 2010;4:198-207.
  • 4 van der Laan TP, Plaat BE, van der Laan BF, Halmos GB. Clinical recommendations on the treatment of neuroendocrine carcinoma of the larynx: A meta-analysis of 436 reported cases. Head Neck 2015;37:707-15.
  • 5 Maithrea N, Ewe S, Pua KC, Mohamad I. Primary large cell neuroendocrine carcinoma of the larynx. Egypt J Ear Nose Throat Allied Sci 2017;18:179-81.